AZN News and Press, AstraZeneca PLC From 03/18/24

2024-03-18 07:04:31 ET Summary Today, we look at Mineralys Therapeutics, a clinical-stage biotechnology company focused on developing treatments for diseases driven by elevated aldosterone levels. The company's sole asset, lorundrostat, is an aldosterone synthase inhibitor that ha...

Expanded savings programs build on company’s longstanding commitment to addressing barriers to access and affordability for patients AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more th...

2024-03-16 12:57:30 ET More on Madrigal Pharmaceuticals Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Ra...

2024-03-14 19:23:16 ET More on Terns Pharmaceuticals Seeking Alpha’s Quant Rating on Terns Pharmaceuticals Historical earnings data for Terns Pharmaceuticals Financial information for Terns Pharmaceuticals Read the full article on Seeking Alpha ...

2024-03-14 11:44:36 ET More on Eli Lilly Eli Lilly and Co (LLY) Cowen's 44th Annual Health Care Conference (Transcript) Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly in pact with ...

2024-03-14 06:00:46 ET In a bid to strengthen its rare disease portfolio, AstraZeneca ( NASDAQ: AZN ) has agreed to acquire biotechnology company Amolyt Pharma for $1.05B, on a cash and debt free basis.... Read the full article on Seeking Alpha For further details see: ...

2024-03-13 18:56:55 ET More on Novartis Novartis And MorphoSys Are A Perfect Match Novartis AG (NVS) Q4 2023 Earnings Call Transcript Novartis AG 2023 Q4 - Results - Earnings Call Presentation Novartis to pay up to $835M for STING antagonist developer IFM Due...

2024-03-13 11:55:57 ET More on AstraZeneca 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript AstraZeneca FY23 Earnings Review: It's OK To Buy Dip On Q4 Bottom Line Miss FDA experts recommend changes to flu sho...

THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD First patients dosed in ATHLOS Phase III trial assessing impact of BREZTRI on integrated cardiopulmonary parameter...

2024-03-12 03:57:11 ET Summary Lexicon Pharmaceuticals is actively working to create shareholder value by pursuing new indications for the lead drug sotagliflozin. The company reported $0.7 million in Inpefa sales for Q4 2023, below expectations, but these are still early days for...